Unique ID issued by UMIN | UMIN000010689 |
---|---|
Receipt number | R000012495 |
Scientific Title | Effect of etidronate therapy on prevention of fracture, bone mineral density and bone turnover markers in osteoporotic patients with severe motor and intellectual disabilities: a randomized controlled trial |
Date of disclosure of the study information | 2013/05/10 |
Last modified on | 2013/05/10 16:01:49 |
Effect of etidronate therapy on prevention of fracture, bone mineral density and bone turnover markers in osteoporotic patients with severe motor and intellectual disabilities: a randomized controlled trial
EOSMID
Effect of etidronate therapy on prevention of fracture, bone mineral density and bone turnover markers in osteoporotic patients with severe motor and intellectual disabilities: a randomized controlled trial
EOSMID
Japan |
osteoporosis
Medicine in general | Endocrinology and Metabolism | Geriatrics |
Orthopedics |
Others
NO
Occurrence of fragile fracture, bone mineral density and bone turnover markers (serum TRAP-5b, serum NTX, serum BAP) are evaluated for oral administration of etidronate versus non-administered controls in osteoporotic patients with severe motor and intellectual disabilities. This is a randomized, open-label, multicenter trial.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
occurrence of fragile fracture
changes of bone mineral density (L2-4) and bone turnover markers (serum TRAP-5b, serum NTX, serum BAP)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
YES
Central registration
4
Treatment
Medicine |
Patients without history of fragile fracture for the past 5 years.
Repeated administration of etidronate (200mg) for 2 weeks, following a cessation for 10 weeks.
Patients without history of fragile fracture for the past 5 years.
Ordinary treatment.
Patients with history of fragile fracture for the past 5 years.
Repeated administration of etidronate (200mg) for 2 weeks, following a cessation for 10 weeks.
Patients with history of fragile fracture for the past 5 years.
Ordinary treatment.
18 | years-old | <= |
Not applicable |
Male and Female
1. Patients with osteoporosis (BMD: less than 70% of YAM)
2. Patients with severe motor and intellectual disabilities (Ohshima's classification: 1,2,3,4)
3. Patients with informed of consent obtained from a parent or other family member.
1. Patients with other diseases presenting low BMD
2. Patients with GERD
500
1st name | |
Middle name | |
Last name | Shigenori Yamamoto |
NHO Shimoshizu National Hospital
Pediatrics
Chiba Yotsukaido Shikawatashi 934-5
043-422-2511
1st name | |
Middle name | |
Last name | Shigenori Yamamoto |
NHO Shimoshizu National Hospital
Pediatrics
Chiba, Yotsukaido, Shikawatashi 934-5
043-422-2511
http://www.hosp.go.jp/~simosizu/
syamamoto3@nifty.com
National Hospital Organization
National Hospital Organization
Other
Japan
NO
国立病院機構下志津病院(千葉県)、国立病院機構愛媛病院(愛媛県)、国立病院機構柳井医療センター(山口県)、国立病院機構青森病院(青森県)、国立病院機構岩手病院(岩手県)、国立病院機構南京都病院(京都府)、国立病院機構高知病院(高知県)、国立病院機構西別府病院(大分県)、国立病院機構千葉東病院(千葉県)、国立病院機構宮崎病院(宮崎県)、国立病院機構香川小児病院(香川県)、国立病院機構医王病院(石川県)、国立病院機構新潟病院(新潟県)、国立病院機構山口宇部医療センター(山口県)、国立病院機構西群馬病院(群馬県)、国立病院機構広島西医療センター(広島県)、国立病院機構名古屋医療センター(愛知県)
2013 | Year | 05 | Month | 10 | Day |
Partially published
Completed
2009 | Year | 12 | Month | 03 | Day |
2010 | Year | 01 | Month | 04 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 03 | Month | 31 | Day |
2013 | Year | 05 | Month | 10 | Day |
2013 | Year | 05 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012495